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5 of the CYP2C8 substrate R-ibuprofen has been reduced in subjects carrying the CYP2C8*3 allele, compared to subjects with the CYP2C8*1/*1 reference genotype (García-Martín et al., 2004) . Accordingly, the in vivo significance of the CYP2C8*3 allele has been somewhat controversial. The frequency of CYP2C8*3 in white subjects is about 10-20% and only about 2% in black subjects (Totah and Rettie, 2005) .
The antimicrobial drug trimethoprim is a selective and moderately potent inhibitor of CYP2C8 in vitro (Wen et al., 2002) . In vivo, trimethoprim has raised the AUC of the CYP2C8 substrates repaglinide and rosiglitazone by 61% and 37%, respectively (Niemi et al., 2004a; Niemi et al., 2004b) . In the present study, we investigated the effects of trimethoprim, given 160 mg twice daily, and of the CYP2C8 genotype, on the pharmacokinetics of 15 mg pioglitazone in 8 non-carriers and 8 carriers of the CYP2C8*3 allele (Table 1 ). The predictability of the trimethoprim-pioglitazone interaction was also evaluated using in vitro pharmacokinetic studies.
6 Methods Subjects. Sixteen healthy volunteers (8 men and 8 women; mean age 21 years, range 19-25 years; Table 1 ) participated in the study after giving written informed consent.
They were recruited from a pool of more than 400 pharmacogenetically characterized subjects genotyped for CYP2C8 alleles. Genotyping for the CYP2C8*3 (c.416G>A, c.1196A>G) and CYP2C8*4 (c.792C>G) alleles was achieved by using Custom TaqMan® SNP genotyping assays on an Applied Biosystems 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Genotyping accuracy was validated against a previously described method (Niemi et al., 2003c) . The participants were selected on the basis of the CYP2C8 genotype and allocated into three groups: CYP2C8*1/*1 (i.e., non-carriers of CYP2C8*3; n=8), CYP2C8*1/*3 (n=5), and CYP2C8*3/*3 (n=3). Only non-carriers of the CYP2C8*4 allele were recruited. None of the subjects had participated in our previous studies on the effects of the CYP2C8*3 allele on the pharmacokinetics of repaglinide (Niemi et al., 2003c; Niemi et al., 2005) . The volunteers were ascertained to be healthy by medical history, physical examination, and routine laboratory tests before entering the study. None of the volunteers used continuous medication, e.g. oral contraceptives, or were smokers.
The sample size was chosen so that a possible clinically significant pharmacokinetic drug interaction can be verified statistically without the use of an unnecessarily large group of healthy subjects. The number of subjects was estimated to be sufficient to detect a 25% change in the AUC 0-∞ of pioglitazone with a power of 90% (alpha-level 5%).
Study design. The study protocol was approved by the Coordinating Ethics
Committee of the Helsinki and Uusimaa Hospital District and the National Agency This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 3, 2007 as DOI: 10.1124 at ASPET Journals on October 14, 2017 dmd.aspetjournals.org Downloaded from for Medicines. A randomized, 2-phase crossover study with a washout period of 4 weeks was carried out. The volunteers received orally for six days 160 mg trimethoprim (Trimetin 160 mg tablet; Vitabalans, Hämeenlinna, Finland) or placebo (Yliopiston apteekki, Helsinki, Finland) twice daily at 8 AM and 8 PM with the exception of the evening dose on day 3, which was administered at 9 PM. On day 3, a single oral dose of 15 mg pioglitazone (one Actos 15 mg tablet; Takeda Europe, London, UK) was administered with 150 ml water at 9 AM, i.e. 1 hour after trimethoprim. The volunteers fasted overnight and had a warm standard meal 3 h and a light standard meal 7 and 11 h after pioglitazone intake.
Sampling. On the days of administration of pioglitazone, a forearm vein of each subject was cannulated with a plastic cannula and kept patent with an obturator.
Timed blood samples were drawn prior to and 1, 2, 3, 4, 5, 7, 9, 12, 24, 48, 72, and 96 h after the administration of pioglitazone. The blood samples (10 ml each) were taken into tubes that contained ethylenediaminetetraacetic acid (EDTA). Plasma was separated within 30 min after blood sampling and stored at −70°C until analysis.
Determination of drug concentrations. Pioglitazone plasma and in vitro samples (0.5 ml) were spiked with 50 µl of internal standard (rosiglitazone, 3 µg/ml in 20% methanol) and 100 µl of perchloric acid (35%), vortex mixed and centrifuged. The DMD #18010 8 residues were dissolved in 100 µl of acetonitrile-water (45:55 v/v) and transferred to autosampler vials.
The concentrations of pioglitazone and its metabolites M-IV and M-III were measured by use of PE SCIEX API 2000 liquid chromatography-tandem mass spectrometry system (Sciex division of MDS, Toronto, Canada) (Lin et al., 2003) .
Chromatography was performed on XTerra RP C 18 column (3.9x100 mm; Waters, Milford, MA, USA) using gradient elution. The mobile phase consisted of 10 mM ammonium acetate (pH 9.5, adjusted with 25% ammonia solution) (A) and and M-III was 0.1 ng/ml and the interday coefficients of variation (CV) were 5-10%, 9-14%, and 5-7% at relevant plasma concentrations, respectively. Trimethoprim did not interfere with the assay.
Plasma trimethoprim concentrations were measured by HPLC with ultraviolet detection (Weber et al., 1983; Svirbely and Pesce, 1987) . The limit of quantification was 0.1 µg/ml, and the interday CVs were less than 5% at relevant concentrations.
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Pharmacokinetics. The pharmacokinetics of pioglitazone were characterized by C max , time to C max , AUC 0-∞ , the dominant elimination half-life (t ½ , the half-life of the phase contributing most to the area under the curve) and the terminal half-life (t ½,terminal ).
The pharmacokinetics of the metabolites M-IV and M-III were characterized by C max , AUC 0-∞ and t ½ . Apparent formation rate constants were calculated for metabolites M-IV and M-III by individual modelling with a 1-compartment first-order formation model. In 15 of the 16 subjects, the plasma concentrations of pioglitazone declined biphasically during both study phases. In one subject (number 5), the concentration declined monophasically during both phases. Therefore, for the dominant elimination phase, the elimination rate constant (k e ) was determined by linear regression analysis using the first log-linear phase of the descending plasma concentration curve. For the slow elimination phase, a terminal elimination rate constant (k e,terminal ) was The C liver /C plasma ratio is the liver(unbound, available to the enzyme)/plasma(total) concentration ratio of trimethoprim, K i is the observed K i of trimethoprim, and the C avg,trimethoprim is the observed average (total) plasma concentration of trimethoprim, which was calculated as follows. Fig. 1 ). The dominant elimination t ½ of pioglitazone was prolonged from 3.9 h to 5.1 h (p < 0.001). However, the peak concentration in plasma (C max ), the time to C max (data not shown), or the terminal t ½ (data not shown) of pioglitazone was not changed significantly by trimethoprim.
The apparent formation rate constant (k f ) of the pioglitazone metabolite M-IV was 27% lower (p < 0.001) during the trimethoprim phase than during the placebo phase (Table 3) . Trimethoprim also lowered the M-IV/pioglitazone AUC 0-∞ ratio (p < 0.001). However, despite the reduced formation rate of the metabolite, the Effect of CYP2C8 genotype. During the placebo phase, the subjects with the CYP2C8*1/*3 or *3/*3 genotype had lower mean plasma concentrations of the parent pioglitazone than did the subjects with the CYP2C8*1/*1 genotype (Fig. 2) line with this finding, the M-IV/pioglitazone and M-III/pioglitazone AUC 0-∞ ratios and apparent formation rate constants were higher in the variant groups than in the CYP2C8*1/*1 group (Table 3 , Fig. 3 ). However, no statistically significant differences existed between the genotype groups in the AUC 0-∞ values of M-IV (Table   3) or M-III (data not shown), not even after weight-adjustment (data not shown).
During the trimethoprim phase, the differences in the pharmacokinetics of pioglitazone between the genotype groups were similar to those during the placebo phase or slightly smaller (Tables 2-3 ). There was no significant difference or even a tendency for differences in the extent of the trimethoprim-pioglitazone interaction between the three genotype groups ( Table 2) . by recombinant CYP2C8 was best described by a model for Michaelis-Menten kinetics with substrate inhibition, whereas the formation by CYP3A4 was best described by sigmoidal (Hill) kinetics (Fig. 4A) . The formation rate of the M-IV metabolite was 5-10 times higher by CYP2C8 than CYP3A4 at clinically relevant pioglitazone concentrations (< 2 µM). Trimethoprim concentration-dependently inhibited M-IV formation in human liver microsomes and recombinant CYP2C8, and the inhibitory effect was best described by the competitive inhibition model, with a mean (±standard error) inhibition constant (K i ) of 38.2±3.9 µM and 34.1±4.0 µM, respectively (Fig. 4B ).
Metabolism of pioglitazone in vitro.
This article has not been copyedited and formatted. The final version may differ from this version. The extent of trimethoprim-pioglitazone interaction (pioglitazone AUC inhibited / pioglitazone AUC control ) could be predicted reasonably accurately in two thirds of the subjects on the basis of the in vitro K i of trimethoprim and its average plasma concentration using a competitive inhibition model with a C liver /C plasma ratio of 2.35 for trimethoprim (Fig. 5) . The equation obtained using regression analysis explained 24% of the variability in the extent of interaction with a mean prediction error of −6%±22%. For 11 of the 16 subjects, the predictions were within ±20% of the observed extent of interaction. Of the five subjects outside the ±20% range, two had the CYP2C8*3/*3 genotype, and two had the CYP2C8*1/*3 genotype.
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Discussion
In the current study, trimethoprim moderately and concentration-dependently increased the AUC 0-∞ of pioglitazone and lowered the ratio of the main primary metabolite M-IV to pioglitazone in plasma, indicating that trimethoprim inhibited the CYP2C8-mediated metabolism of pioglitazone. Trimethoprim also prolonged the dominant elimination t ½ of pioglitazone. However, the terminal t ½ , which seems to reflect a release of pioglitazone from peripheral tissues and is insensitive also to the effect of induction (Jaakkola et al., 2006a), was unaffected by trimethoprim.
Compared to individuals with the CYP2C8*1/*1 genotype, those homozygous or heterozygous for the CYP2C8*3 variant allele had lower plasma concentrations of pioglitazone and a higher rate of metabolite formation. Both the weight adjusted AUC 0-∞ and the M-IV/pioglitazone and M-III/pioglitazone AUC 0-∞ ratios showed a gene-dose effect, with the heterozygous CYP2C8*3 allele carriers in between the homozygous carriers and the non-carrier group. The extent of the trimethoprimpioglitazone interaction, which was independent of the CYP2C8 genotype, could be predicted using the K i value of trimethoprim for CYP2C8 and plasma trimethoprim concentrations.
The adverse effects of the thiazolidinediones pioglitazone and rosiglitazone include fluid retention and peripheral edema, and seem to be dose (concentration) dependent (Hanefeld and Belcher, 2001; Kermani and Garg, 2003) .
Rosiglitazone has also been suspected of increasing the risk of cardiovascular death (Nissen and Wolski, 2007) . Although the interaction of trimethoprim with pioglitazone was moderate, the increase in the AUC of pioglitazone was more than 2-fold in some subjects, and also the AUC of the active metabolite M-IV was increased by trimethoprim. Accordingly, it is possible that a concomitant administration of trimethoprim or other inhibitors of CYP2C8 with pioglitazone could lead to an This article has not been copyedited and formatted. The final version may differ from this version. There has been a lot of controversy concerning the effect of the CYP2C8*3 allele on the disposition of different drugs, and no studies concerning its effect on the pharmacokinetics of pioglitazone have been published previously. In in vitro studies, CYP2C8.3 has had a reduced activity to metabolize paclitaxel, arachidonic acid and amodiaquine (Dai et al., 2001; Bahadur et al., 2002; Parikh et al., 2007) . Surprisingly, in first human studies, carriers of the CYP2C8*3 allele were found to have lower plasma concentrations of repaglinide than the control group homozygous for the CYP2C8*1 allele (Niemi et al., 2003c; Niemi et al., 2005) . Also with rosiglitazone, subjects homozygous for CYP2C8*3 have had an increased clearance compared to subjects homozygous for the CYP2C8*1 allele (Kirchheiner et al., 2006) . On the other hand, some studies have found no significant effects of the CYP2C8*3 genotypes on the pharmacokinetics of repaglinide, rosiglitazone, or paclitaxel (Henningsson et al., 2005; Bidstrup et al., 2006; Pedersen et al., 2006) .
Moreover, the CYP2C8*3 allele has been associated with a reduced clearance and prolonged t ½ of both enantiomers of ibuprofen (García-Martín et al., 2004) . Due to strong linkage disequilibrium, the CYP2C9*2 allele exists commonly in the same haplotype with the CYP2C8*3 allele (Yasar et al., 2002) , which could affect these findings, since ibuprofen is metabolized by both of these CYP enzymes (Hamman et al., 1997) . Thus, the result of the current study, that pioglitazone concentrations are lower in carriers of CYP2C8*3 allele than in non-carriers, together with the previous in vivo results with repaglinide and rosiglitazone (Niemi et al., 2003c; Niemi et al., 2005; Kirchheiner et al., 2006) , suggest that the CYP2C8*3 allele is often associated with an increased CYP2C8 activity phenotype. The extent of the interaction between trimethoprim and pioglitazone, however did not appear to depend on the CYP2C8
genotype.
The earlier information on the contribution of different CYP enzymes to the metabolism of pioglitazone has been discrepant. Thus, the European product information of Actos stated that the metabolism of pioglitazone occurs predominantly via CYP3A4 and CYP2C9 (Lääketietokeskus, 2007) , whereas the U.S. label stated that the major CYP isoforms are CYP2C8 and CYP3A4 (FDA). According to our recent in vitro study, pioglitazone (at 1 µM concentration) is metabolized mainly (60-90%) by CYP2C8, and to a lesser extent (10-40%) by CYP3A4, while other CYP forms play a negligible role (Jaakkola et al., 2006b ). However, previous findings that itraconazole has no effect on the pharmacokinetics of pioglitazone in humans of the activity of CYP2C8; Fig. 4A ) at clinically relevant pioglitazone concentrations of < 2 µM (< 720 ng/ml) (Eckland and Danhof, 2000) , due to the sigmoidal kinetics of M-IV formation by CYP3A4. Sigmoidal kinetics is a common feature of CYP3A4 mediated reactions and a possible cause of overestimation of the role of the CYP form, if too high substrate concentrations are used in vitro. It should be noted that the free fraction of pioglitazone in plasma is less than 3%, and therefore its unbound concentrations at the enzyme site (in the liver) are probably much smaller than its total plasma concentrations. This example emphasizes the need of using relevant concentrations when in vitro to in vivo correlations are made.
Repaglinide and rosiglitazone have been recommended to be used as in vivo probes for CYP2C8-mediated metabolism (Huang et al., 2007) . Repaglinide is a sensitive probe drug, but unlike pioglitazone and rosiglitazone it easily causes hypoglycemia. Moreover, repaglinide is also a substrate of OATP1B1, and its pharmacokinetics are affected by the SLCO1B1 genotype (Niemi et al., 2005) , unlike those of pioglitazone (Kalliokoski et al., 2007) . Gemfibrozil has raised the AUC of rosiglitazone and pioglitazone by 2.3-fold and 3.2-fold, respectively (Niemi et al., 2003a; Jaakkola et al., 2005) . In the present study, trimethoprim increased the AUC of pioglitazone slightly more (by 42%) than it has raised the AUC of rosiglitazone (by 37%), suggesting that the role of CYP2C8 is slightly greater in the metabolism of pioglitazone than in the metabolism of rosiglitazone. In addition, pioglitazone does not inhibit CYP2C8 in vivo (Kajosaari et al., 2006) . Taken together, pioglitazone could serve as a more sensitive in vivo probe for CYP2C8 than rosiglitazone, while having a better single dose safety profile than repaglinide.
In human liver microsomes, trimethoprim inhibited the formation of M-IV from pioglitazone with a K i of 38 µ M, which is comparable to the K i value (32 µM) of trimethoprim for the CYP2C8 model reaction, paclitaxel 6α-hydroxylation This article has not been copyedited and formatted. The final version may differ from this version. (Wen et al., 2002) . If this data were directly extrapolated from in vitro to in vivo, assuming similar trimethoprim concentrations in plasma and at the enzyme site in the liver, the actual interaction between trimethoprim and pioglitazone would be somewhat underestimated. The liver/plasma ratio of trimethoprim in rhesus monkeys has been about 6.5 (Craig and Kunin, 1973) , suggesting that trimethoprim may be concentrated into the liver also in humans. In fact, incorporating the observed K i , average total plasma trimethoprim concentration and degree of interaction into a predictive model, the liver/plasma concentration ratio of trimethoprim was estimated to average 2.4 in the current study. Including the assumption that only 80% of pioglitazone is metabolized by CYP2C8, the C liver /C plasma ratio of trimethoprim was calculated to be 3.4 (data not shown). Thus, the (unbound) trimethoprim concentration available to CYP2C8 in the liver seems to be several-fold higher than the total plasma trimethoprim concentration. Furthermore, it should be noted that the unbound fraction of trimethoprim in plasma is about 55%.
To conclude, trimethoprim moderately increases the plasma concentrations of pioglitazone by inhibiting its CYP2C8-catalyzed biotransformation.
The CYP2C8*3 allele is associated with reduced pioglitazone plasma concentrations and an increased activity of its CYP2C8-mediated metabolism. Thus, both drug interactions and genetic factors can change the pharmacokinetics of pioglitazone, potentially affecting its efficacy and safety.
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